RT Journal Article
SR Electronic
T1 Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.01.24308310
DO 10.1101/2024.06.01.24308310
A1 Sekaggya-Wiltshire, Christine
A1 Mbabazi, Irene
A1 Nabisere-Arinaitwe, Ruth
A1 Banturaki, Grace
A1 Alinaitwe, Lucy
A1 Otalo, Brian
A1 Aber, Florence
A1 Nampala, Juliet
A1 Owor, Rogers
A1 Bayiga, Josephine
A1 Laker Agnes Odongpiny, Eva
A1 Castelnuovo, Barbara
A1 Mayito, Jonathan
A1 Sekadde, Moorine
A1 Pasipanodya, Jotam G.
A1 Turyahabwe, Stavia
A1 Zawedde-Muyanja, Stella
YR 2024
UL http://medrxiv.org/content/early/2024/06/02/2024.06.01.24308310.abstract
AB Introduction Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for Tuberculosis Preventive Therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3HP) pharmacokinetics, pharmacogenomics and their relation with ADRs. Our study aims to describe the pharmacokinetic and pharmacogenomics of 3HP used for TPT, the ADRs and their association with completion rates, and TPT outcomes, providing vital insights for TB control strategies in resource-limited settings.Methods This is an observational cohort study with a nested case-control study. We enrolled consecutive patients initiated on TPT using the 3HP regimen. These are followed up bi-weekly and then monthly during the active phase of treatment and 3 monthly for 2 years following completion of TPT. ADR evaluation includes clinical assessment and liver function tests. Cases are selected from those who experience ADRs, and controls from those who do not. Serum isoniazid and rifapentine concentrations are measured and pharmacogenomic analysis for NAT2 and CYP2E1 polymorphisms are done. Participants are followed up for 2 years to determine TPT outcomes.Analysis The safety profile of 3HP will be assessed using descriptive statistics, including proportions of patients experiencing ADRs and grade 3 or above events related to treatment. Chi-square tests and regression models will determine predictors of ADRs and their impact on treatment completion. Pharmacokinetic-pharmacodynamic modeling will establish population parameters and factors influencing rifapentine and isoniazid concentrations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was sought and approvals received from the Infectious Diseases Institute Research and Ethics Committee (IDI-REC), IREC Ref: 001/2021 and the Uganda National Council of Science and Technology (UNCST), UNCST Folio Number: HS1582ES. Written informed consent is obtained from all participants. Children between 8 and 17 years are requested for assent, in addition to consent from their parents or legally authorized representative. For children less than 8 years, consent is sought from their parents/ legally authorized representative. The study is conducted in accordance with good clinical practice and declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.